Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

DSIJ Intelligence Article rating: 5.0

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why
46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why

46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

DSIJ Intelligence Article rating: 5.0

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

Pharma Giant Expands with Strategic Acquisition in Singapore
Pharma Giant Expands with Strategic Acquisition in Singapore

Pharma Giant Expands with Strategic Acquisition in Singapore

The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations.

DSIJ Intelligence Article rating: 4.0

The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19
Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

The stock gave multibagger returns of 160 per cent in just 1 year whereas BSE Sensex Index is up by 5 per cent.

DSIJ Intelligence Article rating: 3.6

The stock’s 52-week high is Rs 1,678.60 per share while its 52-week low is Rs 489.20 per share.

Strategic Acquisition: Major MedTech Expansion by Indian Pharma Giant
Strategic Acquisition: Major MedTech Expansion by Indian Pharma Giant

Strategic Acquisition: Major MedTech Expansion by Indian Pharma Giant

Zydus Lifesciences Limited has announced its strategic decision to acquire a controlling stake in Amplitude Surgical SA, a France-based company listed on Euronext Paris.

DSIJ Intelligence Article rating: 3.3

Zydus Lifesciences Limited, a prominent player in the Indian pharmaceutical sector, is currently trading at a stock price of Rs 900 with a market capitalization of over Rs 90,000 crores.

New Diabetes Drug Launched: Affordable Treatment Revolution in India
New Diabetes Drug Launched: Affordable Treatment Revolution in India

New Diabetes Drug Launched: Affordable Treatment Revolution in India

Alkem's commitment to global health improvement is reflected in its diverse product offerings and international presence.

DSIJ Intelligence Article rating: 5.0

Alkem Laboratories Ltd. is a prominent Indian pharmaceutical company known for its high-quality medicines over the past 50 years.

RSS
123456

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR